Diametric Capital’s Ovid Therapeutics OVID Stock Holding History

Diametric Capital’s Portfolio OVID Stock Details OVID Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-43,262	Closed	-$96K	–	628
2026 Q1	$96K	Buy	+43,262	New	+$77.3K	0.03%	418

Other funds holding OVID

Jupiter Topco New York $245B AUM

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Diametric Capital's OVID Position: Q2 2026 in Review

Diametric Capital sold out of Ovid Therapeutics (OVID) in Q2 2026, closing a stake of 43,262 shares — an estimated $96K sold.

Diametric Capital first reported a position in OVID in Q1 2026 and held it in 1 quarter. The position peaked at $96K in Q1 2026. 131 funds tracked by Wall St. Rank hold OVID as of Q2 2026.

Diametric Capital reported no remaining Ovid Therapeutics position as of Q2 2026 after selling out during the quarter.
Diametric Capital sold 43,262 Ovid Therapeutics shares in Q2 2026, an estimated $96K.
Diametric Capital first reported a position in Ovid Therapeutics in Q1 2026 and held it in 1 quarter.
Diametric Capital's Ovid Therapeutics position peaked at $96K in Q1 2026.
131 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q2 2026.

Based on Diametric Capital's 13F filing for Q2 2026, filed 14 Aug 2026.